Matt Hewitt
Stock Analyst at Craig-Hallum
(2.68)
# 2,155
Out of 5,032 analysts
40
Total ratings
54.05%
Success rate
3.64%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $15.39 | +133.92% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.44 | +86.34% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.71 | +121.40% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $27.32 | +17.13% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $29.90 | +114.05% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.32 | +657.58% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $19.31 | +55.36% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.61 | +334.78% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $152.60 | +31.06% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.66 | +502.41% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $8.53 | +251.70% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.74 | +53,895.68% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $15.39
Upside: +133.92%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.44
Upside: +86.34%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.71
Upside: +121.40%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $27.32
Upside: +17.13%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $29.90
Upside: +114.05%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.32
Upside: +657.58%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $19.31
Upside: +55.36%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.61
Upside: +334.78%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $152.60
Upside: +31.06%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.66
Upside: +502.41%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $8.53
Upside: +251.70%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.74
Upside: +53,895.68%